lunedì, 20 marzo 2023

Notizie AIOM – anno XV n. 642

11 Settembre 2017

FDA Grants Cemiplimab Breakthrough Designation for CSCC

September 8, 2017 - The FDA has granted a breakthrough therapy designation to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, according to Regeneron Pharmaceuticals, ...
Leggi tutto

8 Settembre 2017

Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis

Dietary fat may play a role in lung carcinogenesis. Findings from epidemiologic studies, however, remain inconsistent. In this pooled analysis of 10 prospective cohort studies from the United States, Europe, and Asia, we evaluated the associations of total and specific types ...
Leggi tutto

8 Settembre 2017

Lo screening può salvarti la vita!

Cittadinanzattiva ha lanciato una campagna informativa digital sui principali social network, con hashtag #nonaspettare, di supporto al programma nazionale di screening per il cancro alla mammella, al colon retto e alla cervice uterina. Obiettivo è quello di raggiungere ...
Leggi tutto

8 Settembre 2017

Distrust in the End-Of-Life Care Provided to a Parent and Long-Term Negative Outcomes Among Bereaved Adolescents: A Population-Based Survey Study

Previous research shows that the death of a parent places children at risk for a number of negative outcomes. The role of trust in health care at the end of life has been acknowledged as crucial for patients and adult family members. However, the consequences of children’s ...
Leggi tutto

8 Settembre 2017

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7, 2017 - The FDA has placed partial clinical holds on 3 trials assessing nivolumab-based combinations in patients with relapsed/refractory multiple myeloma. The phase III CheckMate-602, phase I CheckMate-039, and phase II CA204142 are affected by the decision. ...
Leggi tutto

8 Settembre 2017

FDA Places Holds on Several Durvalumab Combination Trials

September 7, 2017 - The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies. The agency ...
Leggi tutto

8 Settembre 2017

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 5, 2017 - The European Commission (EC) has approved pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy. ...
Leggi tutto

8 Settembre 2017

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

The data reported herein were accepted for assessment by the US Food and Drug Administration for Biologics License Application under priority review to establish the clinical benefit of durvalumab as second-line therapy for locally advanced or metastatic urothelial carcinoma ...
Leggi tutto

8 Settembre 2017

Oxycodone for cancer-related pain

Many people with cancer experience moderate to severe pain that requires treatment with strong opioids, such as oxycodone and morphine. Strong opioids are, however, not effective for pain in all people, neither are they well-tolerated by all people. The aim of this review ...
Leggi tutto

8 Settembre 2017

Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity

Eligibility criteria and screening procedures are designed to optimize the scientific yield and maximize the safety of clinical trials. However, they may also heighten trial complexity, hinder enrollment, decrease generalizability, and increase costs. We analyzed the types ...
Leggi tutto